Effect of lipoteichoic acid on IL-2 and IL-5 release from T lymphocytes in asthma and COPD

International Immunopharmacology

Volumn 13, Issue 3, 2012, Pages 284-291

  Mat, Zeynep ^a   Grensemann, Barbara ^a   Yakin, Yakup ^a   Knobloch, Jürgen ^a,b   Koch, Andrea ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Asthma; COPD; Gram positive bacteria; Infection defense; Lipoteichoic acid (LTA); T H2 T C2 lymphocytes

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 5; LIPOTEICHOIC ACID;

ADULT; AIRFLOW; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SMOKING; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; TH2 CELL;

ADULT; AGED; ASTHMA; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-5; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TEICHOIC ACIDS; TH2 CELLS;

EID: 84861441715     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.04.005     Document Type: Article

References (66)

1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165-85.
2. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 2007;4(8):626-34. (Pubitemid 350291625)
3. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 2009;6(8):638-47.
4. Cornwell WD, Kim V, Song C, Rogers TJ. Pathogenesis of inflammation and repair in advanced COPD. Semin Respir Crit Care Med 2010;31(3):257-66.
5. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418-24. (Pubitemid 36216426)
6. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118(11):3546-56.
7. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8(3):183-92. (Pubitemid 351323287)
8. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204-12.
9. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(4):367-70. (Pubitemid 41699698)
10. Majori M, Corradi M, Caminati A, Cacciani G, Bertacco S, Pesci A. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol 1999;103(3 Pt 1):458-62. (Pubitemid 29136299)
11. Di Stefano A, Caramori G, Capelli A, Gnemmi I, Ricciardolo FL, Oates T, et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 2004;24(1):78-85. (Pubitemid 39029072)
12. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004;1(1):e8.
13. Barczyk A, Pierzchata W, Kon OM, Cosio B, Adcock IM, Barnes PJ. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006;117(6):1484-92. (Pubitemid 43795735)
14. Schild K, Knobloch J, Yakin Y, Jungck D, Urban K,Müller K, et al. IL-5 release of CD4+ non-effector lymphocytes is increased in COPD-modulating effects of moxifloxacin and dexamethasone. Int Immunopharmacol 2011;11(4):444-8.
15. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2(8):675-80. (Pubitemid 32747155)
16. Knobloch J, Schild K, Jungck D, Urban K, Müller K, Schweda EK, et al. The T-helper cell type 1 immune response to gram-negative bacterial infections is impaired in COPD. Am J Respir Crit Care Med 2011;183(2):204-14.
17. Komai-Koma M, Gilchrist DS, Xu D. Direct recognition of LPS by human but not murine CD8+ T cells via TLR4 complex. Eur J Immunol 2009;39(6):1564-72.
18. Koch A, Knobloch J, Dammhayn C, Raidl M, Ruppert A, Hag H, et al. Effect of bacterial endotoxin LPS on expression of INF-gamma and IL-5 in T-lymphocytes from asthmatics. Clin Immunol 2007;125(2):194-204. (Pubitemid 47562901)
19. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008;226:19-28.
20. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88(3):825-32.
21. Monso E, Ruiz J, Rosell A,Manterola J, Fiz J,Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152(4 Pt 1): 1316-20.
22. KraftM. The role of bacterial infections in asthma. Clin ChestMed 2000;21(2):301-13. (Pubitemid 30434641)
23. Draing C, Sigel S, Deininger S, Traub S, Munke R, Mayer C, et al. Cytokine induction by gram-positive bacteria. Immunobiology 2008;213(3-4):285- 96.
24. Deininger S, Traub S, Aichele D, Rupp T, Baris T, Möller HM, et al. Presentation of lipoteichoic acid potentiates its inflammatory activity. Immunobiology 2008;213(6): 519-29.
25. Morath S, Geyer A, Hartung T. Structure-function relationship of cytokine induction by lipoteichoic acid from staphylococcus aureus. J Exp Med 2001;193(3):393-7. (Pubitemid 32524522)
26. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002;2(3):171-9. (Pubitemid 34462452)
27. Stankiewicz W, Dabrowski MP, Chcialowski A, Plusa T. Cellular and cytokine immunoregulation in patients with chronic obstructive pulmonary disease and bronchial asthma. Mediators Inflamm 2002;11(5):307-12. (Pubitemid 35335221)
28. Cote-Sierra J, Foucras G, Guo L, Young HA Chiodettti L, Hu-Li J, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A 2004;101(11): 3880-5. (Pubitemid 38381071)
29. Rohde G, Gevaert P, Holappels G, Fransen L, Borg I, Wiethege A, et al. Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2004;135(1):54-61. (Pubitemid 39279432)
30. Walsh GM. Novel cytokine-directed therapies for asthma. DiscovMed 2011;11(59): 283-91.
31. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6): 532-55. (Pubitemid 47403272)
32. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31(1):143-78.
33. Koch A, Raidl M, Lux M, Müller K, Bünning H, Humme S, et al. IL-2-induced T-bet expression and IFNgamma release in lymphocytes from asthmatics - role of MAPkinase ERK-1/-2, p38(MAPK) and effect of dexamethasone. Respir Med 2007;101(6):1321-30. (Pubitemid 46667660)
34. Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol 2008;180(5):3478-84.
35. Stanciu LA, Roberts K, Papadopoulos NG, Cho SH, Holgate ST, Coyle AJ, et al. IL-4 increases type 2, but not type 1, cytokine production in CD8+ T cells from mild atopic asthmatics. Respir Res 2005;6:67.
36. Jeffery PK. Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease. Novartis Found Symp 2001;234:149-61.
37. Domagala-Kulawik J, Hoser G, Dabrowska M, Chazan R. Increased proportion of Fas positive CD8+cells in peripheral blood of patients with COPD. Respir Med 2007;101(6):1338-43. (Pubitemid 46667656)
38. Koch A, Gaczkowski M, Sturton G, Staib P, Schinköthe T, Klein E, et al. Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking. Eur Respir J 2007;29(1):42-50. (Pubitemid 46091996)
39. Barceló B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006;145(3):474-9. (Pubitemid 44252490)
40. Tsai LC, Tang RB, Hung MW, Chen HM, Tsai SJ. Expression of serum IL-2, IL-2R, and CD8 levels during hyposensitization in house-dust-sensitive asthmatics. J Asthma 1990;27(5):307-13.
41. Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. J Asthma 2001;38(8):665-71. (Pubitemid 33104247)
42. Alexander AG, Barkans J,Moqbel R, Barnes NC, Kay AB, Corrigan CJ. Seruminterleukin- 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Thorax 1994;49:1231-3.
43. Park CS, Lee SM, Chung SW, Uh S, Kim HAT, Kim YH. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest 1994;106(2):400-6. (Pubitemid 24252033)
44. Park SW, Kim DJ, Chang HS, Park SJ, Lee YM, Park JS, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. Int Arch Allergy Immunol 2003;131(4):283-90. (Pubitemid 36980761)
45. Hamzaoui A, Brahim MB, Zhioua A, Ayed K, Hamzaoui K. Inflammatory response in induced sputum mononuclear cells from patients with acute exacerbation of asthma. Mediators Inflamm 2000;9(3-4):147-53.
46. Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol 2007;150(1):22-9. (Pubitemid 47383287)
47. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5(10):987-95. (Pubitemid 41057715)
48. Morr M, Takeuchi O, Akira S, Simon MM, Mühlradt PF. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 2002;32(12):3337-47. (Pubitemid 36024371)
49. Schröder NW, Morath S, Alexander C, Hamann L, Hartung T, Zähringer U, et al. Lipoteichoic acid (LTA) of Streptococcus pneumonia and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, Lipopolysaccharidebinding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278(18):15587-94. (Pubitemid 36799667)
50. Hoogerwerf JJ, de Vos AF, Bresser P, van der Zee JS, Pater JM, de Boer A, et al. Lung inflammation induced by lipoteichoic acid or Lipopolysaccharide in humans. Am J Respir Crit Care Med 2008;178(1):34-41. (Pubitemid 351919191)
51. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007;19(1):39-45. (Pubitemid 46084902)
52. Loza MJ, Peters SP, Penn RB. Atopy, asthma, and experimental approaches based on the linear model of T cell maturation. Clin Exp Allergy 2005;35(1):8-17. (Pubitemid 40188264)
53. Loppow D, Huland E, Heinzer H, Grönke L, Magnussen H, Holz O, et al. Interleukin- 2 inhalation therapy temporarily induces asthma-like airway inflammation. Eur J Med Res 2007;12(11):556-62. (Pubitemid 350104059)
54. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY. et al Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178:1002-8.
55. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84.
56. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, et al. Sputum IL-5 concentration is associated with sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration 2009;78(3):256-62.
57. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009;30(10):475-87.
58. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T. Induction of cross-tolerance by Lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001;166(8): 5161-7. (Pubitemid 32280731)
59. Thomson NC, Sandilands GP, Gray K, Reid F. Increase in peripheral blood null cells in extrinsic bronchial asthma. Clin Exp Immunol 1977;30(3):429-33. (Pubitemid 8267982)
60. Larramendy ML, Knuutila S. Increased frequency of micronuclei in B and T8 lymphocytes from smokers. Mutat Res 1991;259(2):189-95.
61. Schaberg T, Theilacker C, Nitschke OT, Lode H. Lymphocytes subsets in peripheral blood and smoking habits. Lung 1997;175(6):387-94. (Pubitemid 27431216)
62. Rufino R, Costa CH, Souza HS, Madi K, Silva JR. Induced sputum and peripheral blood cell profile in chronic obstructive pulmonary disease. J Bras Pneumol 2007;33(5):510-8.
63. Foti M, Granucci F, Pelizzola M, Beretta O, Ricciardi-Castagnoli P. Dendritic cells in pathogen recognition and induction of responses: a functional genomics approach. J Leukoc Biol 2006;79(5):913-6. (Pubitemid 44835577)
64. Naik SH, Metcalf D, van Nieuwenhuijze A, Wicks I, Wu L, O'Keeffe M. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 2006;7(6):663-71. (Pubitemid 43797348)
65. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 2006;18(4):503-11. (Pubitemid 43947581)
66. Endo H, Iwamoto I, Nakajima H, Yoshida S. In vitro interleukin-5 production of peripheral blood mononuclear cells is increased in patients with asthma. Int Arch Allergy Immunol 1993;101(4):425-30. (Pubitemid 23250499)